Interrogating the haemodynamic effects of haemodialysis arteriovenous fistula on cardiac structure and function

Sokratis Stoumpos1,2, Alastair Rankin3,4, Pauline Hall Barrientos5

  • 1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. sokratis.stoumpos@ggc.scot.nhs.uk.

Scientific Reports
|September 14, 2021
PubMed

Insights

Arteriovenous fistula (AVF) creation for haemodialysis significantly increases left ventricular (LV) mass in chronic kidney disease (CKD) patients. This cardiac remodelling is directly proportional to fistula blood flow, highlighting potential cardiovascular risks.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Medical Imaging

Background:

  • Arteriovenous fistula (AVF) is the preferred vascular access for maintenance haemodialysis.
  • AVF creation may lead to maladaptive cardiovascular remodelling in patients with chronic kidney disease (CKD).
  • Understanding the cardiac impact of AVF is crucial for managing CKD patients undergoing haemodialysis.

Purpose of the Study:

  • To investigate the effect of AVF creation on cardiac structure and function in CKD patients.
  • To assess changes in left ventricular (LV) mass, volumes, ejection fraction, and cardiac output post-AVF creation.
  • To determine the relationship between fistula blood flow and cardiac remodelling.

Main Methods:

  • Prospective cohort study involving 40 CKD patients undergoing first AVF creation.
  • Cardiac magnetic resonance (CMR) imaging performed at baseline and 6 weeks post-AVF creation.
  • Ultrasound measurements of fistula blood flow at 6 weeks.

Main Results:

  • A significant mean increase of 7.4 g in LV mass was observed 6 weeks after AVF creation (p=0.02).
  • Significant increases in LV end-diastolic volumes and cardiac output were noted post-AVF creation.
  • Increased LV mass was proportional to fistula blood flow, with higher flows correlating with greater increases.

Conclusions:

  • AVF creation for haemodialysis leads to significant increases in LV myocardial mass within weeks.
  • The observed cardiac remodelling is directly proportional to fistula blood flow.
  • These findings highlight the potential for AVF to induce cardiovascular changes that warrant monitoring in CKD patients.

Related Concept Videos

Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
460
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
197
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
296
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
540
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
105
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
581